Experience of intravitreal injections in a tertiary Hospital in Oman

Research output: Contribution to journalArticle

Abstract

Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman. Design: Retrospective chart review. Methods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital. Results: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8%), ranibizumab (32.3%), triamcinolone (7.5%), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9%), choroidal neovascularization (24.3%), and retinal vein occlusive diseases (11.5%). Serious adverse events were rare, and they occurred as ocular (0.9% per patient) and systemic (3.3% per patient). There were 42 eyes received intravitreal triamcinolone, and 24% of them developed intraocular hypertension that required only medical treatment. Conclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety.

Original languageEnglish
Pages (from-to)166-170
Number of pages5
JournalOman Journal of Ophthalmology
Volume8
Issue number3
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Oman
Intravitreal Injections
Tertiary Care Centers
Triamcinolone
Retinal Vein
Choroidal Neovascularization
Injections
Endophthalmitis
Macular Edema
Eye Diseases
Antifungal Agents
Outpatients
Therapeutics
Anti-Bacterial Agents
Hypertension
Safety

Keywords

  • Antivascular endothelial growth factors
  • choroidal neovascularization
  • diabetic macular edema
  • intravitreal
  • Oman
  • retina
  • retinal vascular occlusion

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Experience of intravitreal injections in a tertiary Hospital in Oman. / Al-Hinai, Ahmed S.

In: Oman Journal of Ophthalmology, Vol. 8, No. 3, 01.10.2015, p. 166-170.

Research output: Contribution to journalArticle

@article{a5444668b4364d65a0b06f124bdf429c,
title = "Experience of intravitreal injections in a tertiary Hospital in Oman",
abstract = "Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman. Design: Retrospective chart review. Methods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital. Results: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8{\%}), ranibizumab (32.3{\%}), triamcinolone (7.5{\%}), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9{\%}), choroidal neovascularization (24.3{\%}), and retinal vein occlusive diseases (11.5{\%}). Serious adverse events were rare, and they occurred as ocular (0.9{\%} per patient) and systemic (3.3{\%} per patient). There were 42 eyes received intravitreal triamcinolone, and 24{\%} of them developed intraocular hypertension that required only medical treatment. Conclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety.",
keywords = "Antivascular endothelial growth factors, choroidal neovascularization, diabetic macular edema, intravitreal, Oman, retina, retinal vascular occlusion",
author = "Al-Hinai, {Ahmed S.}",
year = "2015",
month = "10",
day = "1",
doi = "10.4103/0974-620X.169896",
language = "English",
volume = "8",
pages = "166--170",
journal = "Oman Journal of Ophthalmology",
issn = "0974-620X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Experience of intravitreal injections in a tertiary Hospital in Oman

AU - Al-Hinai, Ahmed S.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman. Design: Retrospective chart review. Methods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital. Results: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8%), ranibizumab (32.3%), triamcinolone (7.5%), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9%), choroidal neovascularization (24.3%), and retinal vein occlusive diseases (11.5%). Serious adverse events were rare, and they occurred as ocular (0.9% per patient) and systemic (3.3% per patient). There were 42 eyes received intravitreal triamcinolone, and 24% of them developed intraocular hypertension that required only medical treatment. Conclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety.

AB - Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman. Design: Retrospective chart review. Methods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital. Results: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8%), ranibizumab (32.3%), triamcinolone (7.5%), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9%), choroidal neovascularization (24.3%), and retinal vein occlusive diseases (11.5%). Serious adverse events were rare, and they occurred as ocular (0.9% per patient) and systemic (3.3% per patient). There were 42 eyes received intravitreal triamcinolone, and 24% of them developed intraocular hypertension that required only medical treatment. Conclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety.

KW - Antivascular endothelial growth factors

KW - choroidal neovascularization

KW - diabetic macular edema

KW - intravitreal

KW - Oman

KW - retina

KW - retinal vascular occlusion

UR - http://www.scopus.com/inward/record.url?scp=84948777006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948777006&partnerID=8YFLogxK

U2 - 10.4103/0974-620X.169896

DO - 10.4103/0974-620X.169896

M3 - Article

VL - 8

SP - 166

EP - 170

JO - Oman Journal of Ophthalmology

JF - Oman Journal of Ophthalmology

SN - 0974-620X

IS - 3

ER -